nach oben

Journal of Neural Transmission

Erschienen in:

13.02.2019 | Psychiatry and Preclinical Psychiatric Studies - Review Article

Dopamine in psychiatry: a historical perspective

verfasst von: Paul Bernard Foley

Erschienen in: Journal of Neural Transmission | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Dopamine is the principal transmitter of several central nervous system pathways originating in the midbrain and critically involved in motor activity, learning and motivation, disruptions of which have been implicated in a number of disorders, including Parkinson disease and schizophrenia. Dopamine played a particularly significant role in the history of neurochemistry. Following a series of investigations between 1957 and 1965, commencing in the laboratory and completed in the clinic, the significance of chemical neurotransmission for normal CNS function was first demonstrated in the case of dopamine.

Andén N-E, Butcher SG, Corrodi H, Fuxe K, Ungerstedt U (1970) Receptor activity and turnover of dopamine and noradrenaline after neuroleptics. Eur J Pharmacol 11:303–314CrossRefPubMed

Ashok AH, Marques TR, Jauhar S, Nour MM, Goodwin GM, Young AH, Howes OD (2017) The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment. Mol Psychiatry 22:666–679CrossRefPubMedPubMedCentral

Bannon MJ, Roth RH (1983) Pharmacology of mesocortical dopamine neurons. Pharmacol Rev 35:53–68PubMed

Baumeister AA, Francis JL (2002) Historical development of the dopamine hypothesis of schizophrenia. J Hist Neurosci 11:265–277CrossRefPubMed

Belujon P, Grace AA (2017) Dopamine system dysregulation in major depressive disorders. Int J Neuropsychopharmacol 20:1036–1046CrossRefPubMedPubMedCentral

Bertler Å, Rosengren E (1959) Occurrence and distribution of dopamine in brain and other tissues. Experientia 15:10–11CrossRefPubMed

Birkmayer W, Hornykiewicz O (1961) Der l-3,4-Dioxyphenylalanin (= DOPA)-Effekt bei der Parkinson-Akinese. Wr klin Wschr 73:787–788

Carlsson A (1959) The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol Rev 11:490–493PubMed

Carlsson A (1988) The current status of the dopamine hypothesis. Neuropsychopharmacology 1:179–186CrossRefPubMed

Carlsson A (1998) Arvid Carlsson. In: LR Squire (ed) The history of neuroscience in autobiography. vol 2, pp 28–66. Academic Press, San Diego

Carlsson M, Carlsson A (1990) Interactions between glutamatergic and monoaminergic systems within the basal ganglia: implications for schizophrenia and Parkinson’s disease. Trends Neurosci 13:272–276CrossRefPubMed

Carlsson A, Lindqvist M (1963) Effect of chlorpromazine or haloperidol on the formation of 3-hydroxytyramine and normetanephrine in mouse brain. Acta Pharmacol 20:140–144CrossRef

Carlsson A, Lindqvist M, Magnusson T (1957) 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180:1200CrossRefPubMed

Coppen A (1967) The biochemistry of affective disorders. Br J Psychiatry 113:1237–1264CrossRefPubMed

Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192:481–483CrossRefPubMed

Dale E, Bang-Andersen B, Sánchez C (2015) Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs. Biochem Pharmacol 95:81–97CrossRefPubMed

Davis KL, Kahn R, Ko G, Davidson M (1991) Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148:1474–1486CrossRefPubMed

Degkwitz R, Frowein R, Kulenkampff C, Mohs U (1960) Über die Wirkungen des L-DOPA beim Menschen und deren Beeinflussung durch Reserpin, Iproniazid und Vitamin B₆. Klin Wschr 38:120–123CrossRefPubMed

Dunlop BW, Nemeroff CB (2007) The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 64:327–337CrossRefPubMed

Ehringer H, Hornykiewicz O (1960) Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin Wschr 38:1236–1239CrossRefPubMed

Engel J, Carlsson A (1977) Catecholamines and behavior. Curr Dev Psychopharmacol 4:1–32PubMed

Faraone SV (2018) The pharmacology of amphetamine and methylphenidate: relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neurosci Biobehav Rev 87:255–270CrossRefPubMedPubMedCentral

Foley PB (2003) The dopamine and l-DOPA story. In: Beans, roots and leaves. A history of the chemical therapy of parkinsonism. Tectum, Marburg, pp 333–387

Foley PB (2014) Sons and daughters beyond your control: episodes in the prehistory of the attention deficit/hyperactivity syndrome. Atten Defic Hyperact Disord 6:125–151CrossRefPubMed

Foley PB (2019) Psychopharmacology: a brief overview of its history. In: Riederer P, Laux G, Mulsant B, Le W, Nagatsu T (eds) NeuroPsychopharmacotherapy. Springer, Vienna (in press)

Hökfelt T (2010) Looking at neurotransmitters in the microscope. Prog Neurobiol 90:101–118CrossRefPubMed

Horn AS, Snyder SH (1971) Chlorpromazine and dopamine: conformational similarities that correlate with the antischizophrenic activity of phenothiazine drugs. Proc Natl Acad Sci USA 68:2325–2328CrossRefPubMedPubMedCentral

Hornykiewicz O (1992) From dopamine to Parkinson’s disease: a personal research record. In: Samson F, Adelman G (eds) The neurosciences: paths of discovery II. Birkhäuser, Boston, pp 125–147

Johnstone EC, Crow TJ, Frith CD, Carney MW, Price JS (1978) Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet 1:848–851CrossRefPubMed

Kendler KS, Schaffner KF (2011) The dopamine hypothesis of schizophrenia: an historical and philosophical analysis. Philos Psychiatr Psychol 18:41–63CrossRef

Kety SS (1962) Résumé: I. Biochimie. In: Ajuriaguerra JD (ed) Monoamines et système nerveux central. Symposium Bel-Air, Genève, Septembre 1961. Georg et Cie, Genève, pp 263–268

Ledonne A, Mercuri NB (2017) Current concepts on the physiopathological relevance of dopaminergic receptors. Front Cell Neurosci 11:27CrossRefPubMedPubMedCentral

Montagu KA (1957) Catechol compounds in rat tissues and in brains of different animals. Nature 180:244–245CrossRefPubMed

Mulinari S (2012) Monoamine theories of depression: historical impact on biomedical research. J Hist Neurosci 21:366–392CrossRefPubMed

Nutt DJ, Lingford-Hughes A, Erritzoe D, Stokes PRA (2015) The dopamine theory of addiction: 40 years of highs and lows. Nature Rev Neurosci 16:305–312CrossRef

Poirier LJ, Sourkes TL (1980) This week’s Citation Classic. Curr Contents 25:14

Raab W (1948) Specific sympathomimetic substance in the brain. Am J Physiol 152:324–339CrossRefPubMed

Randrup A, Munkvad I (1974) Pharmacology and physiology of stereotyped behavior. J Psychiatr Res 11:1–10CrossRefPubMed

Sano I (1960) Biochemistry of the extrapyramidal system. Shinkei Kenkyu no Shimpo (Adv Neurol Sci) 5:42–48

Sano HS (2000) Biochemistry of the extrapyramidal system. Park Rel Disord 6:1–6CrossRef

Sano I, Gamo T, Kakimoto Y, Taniguchi K, Takesada M, Nishinuma K (1959) Distribution of catechol compounds in human brain. Biochim Biophys Acta 32:586–587CrossRefPubMed

Sano I, Taniguchi K, Gamo T, Takesada M, Kakimoto Y (1960) Die Katechinamine im Zentralnervensystem. Klin Wschr 38:57–62CrossRefPubMed

Schildkraut JJ (1965) The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 509:509–522CrossRef

Seeman P (1987) Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1:133–152CrossRefPubMed

Seeman P, Lee T (1975) Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188:1217–1219CrossRefPubMed

Seeman P, Chau-Wong M, Tedesco J, Wong K (1975) Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc Natl Acad Sci USA 72:4376–4380CrossRefPubMedPubMedCentral

Sharma A, Couture J (2014) A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). Ann Pharmacother 48:209–225CrossRefPubMed

Snyder SH (1982) Schizophrenia. Lancet 2:970–973CrossRefPubMed

Tamminga CA, Cascella NG, Lahti RA, Lindberg M, Carlsson A (1992) Pharmacologic properties of (–)-3PPP (preclamol) in man. J Neural Transm 88:165–175CrossRef

Toda M, Abi-Dargham A (2007) Dopamine hypothesis of schizophrenia: making sense of it all. Curr Psychiatry Rep 9:329–336CrossRefPubMed

van Rossum JM (1967) The significance of dopamine-receptor blockade for the action of neuroleptic drugs. In: Neuro-psycho-pharmacology. Proceedings of the fifth international congress of the Collegium Internationale Neuro-psychopharmacologicum, 28th–31st March 1966. Excerpta Medica Foundation, Amsterdam, pp 321–329

van Enkhuizen J, Janowsky DS, Olivier B, Minassian A, Perry W, Young JW, Geyer MA (2015) The catecholaminergic-cholinergic balance hypothesis of bipolar disorder revisited. Eur J Pharmacol 753:114–126CrossRefPubMed

Vane JR, Wolstenholme GEW, O’Connor M (eds) (1960) CIBA foundation symposium jointly with committee for symposia on drug action on adrenergic mechanisms (28th–31st March 1960). J. & A. Churchill, London

Vogt M (1960) Central adrenergic mechanisms. Chairman’s opening remarks. In: Vane JR, Wolstenholme GEW, O’Connor M (eds) CIBA foundation symposium jointly with committee for symposia on drug action on adrenergic mechanisms (28th–31st March 1960). J. & A. Churchill, London, pp 382–385

Wise RA (2004) Dopamine, learning and motivation. Nat Rev Neurosci 5:483–494CrossRefPubMed

Titel: Dopamine in psychiatry: a historical perspective
verfasst von: Paul Bernard Foley
Publikationsdatum: 13.02.2019
Verlag: Springer Vienna
Erschienen in: Journal of Neural Transmission / Ausgabe 4/2019
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-019-01987-0

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

23.04.2024 | Parkinson-Krankheit | Podcast | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Dopamine in psychiatry: a historical perspective

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Checkpointhemmer auch bei MS sicher

Update Neurologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2019

Adenosine heteroreceptor complexes in the basal ganglia are implicated in Parkinson’s disease and its treatment

Journal of Neural Transmission: a scientific journal devoted since 1950 to the translation of neuroscience into clinical practice

Dopaminergic modulation of striatal function and Parkinson’s disease

Tyrosine-hydroxylase immunoreactivity in the mouse transparent brain and adrenal glands

Classical dopamine agonists

Association study and a systematic meta-analysis of the VNTR polymorphism in the 3′-UTR of dopamine transporter gene and attention-deficit hyperactivity disorder

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Checkpointhemmer auch bei MS sicher

Update Neurologie